Yes, Azstarys is a controlled substance. However, its classification is more nuanced than most ADHD medications. The drug contains two active ingredients that fall under different federal schedules, which affects how it’s prescribed and reflects its designed-in abuse deterrence.
How Azstarys Is Scheduled
Azstarys contains two components: dexmethylphenidate, a well-known stimulant classified as Schedule II (the same category as Adderall and Ritalin), and serdexmethylphenidate, a prodrug that the DEA placed in Schedule IV in May 2021. Schedule IV substances are considered to have a lower potential for abuse than Schedule II drugs. Examples of other Schedule IV medications include benzodiazepines like lorazepam and sleep aids like zolpidem.
Because the finished capsule contains both a Schedule II and a Schedule IV ingredient, the overall product is dispensed under Schedule II rules. That’s the more restrictive category, so in practice, Azstarys carries the same prescription requirements as other methylphenidate-based ADHD medications. Your doctor cannot call it in by phone in most states, refills aren’t allowed on the same prescription, and you’ll need a new written or electronic prescription each time.
Why One Ingredient Got a Lower Schedule
The reason serdexmethylphenidate landed in Schedule IV comes down to how the molecule works. It’s a prodrug, meaning it has no stimulant effect on its own. It only becomes active dexmethylphenidate after enzymes in the lower digestive tract break it apart. This conversion process is slow and can’t easily be bypassed.
In a small abuse-potential study of 30 participants, serdexmethylphenidate injected intravenously produced effects statistically similar to placebo. Because the prodrug needs the gut to activate it, snorting or injecting it doesn’t deliver the rapid high that makes traditional stimulants attractive for misuse. That finding was central to the DEA’s decision to place it in the lower schedule.
Each Azstarys capsule is built around this design: 70% of the active content is the slower-converting prodrug, while only 30% is immediate-release dexmethylphenidate. The smaller immediate-release portion kicks in quickly (effects begin within about 30 minutes to one hour), while the prodrug portion sustains the effect for up to 13 hours in some analyses, with a reliably demonstrated duration of about 9 hours in the primary clinical trial.
What the Controlled Substance Label Means for You
Despite the lower-schedule prodrug component, the FDA label for Azstarys carries a boxed warning about abuse, misuse, and addiction. This is standard for all CNS stimulants approved for ADHD, not unique to this drug. The warning notes that the risk of overdose and death increases with higher doses or unapproved methods of administration like snorting or injection.
In practical terms, the Schedule II designation means:
- Prescription limits. Most states cap Schedule II prescriptions at a 30-day supply, and many insurance plans enforce this as well.
- No automatic refills. You’ll need a new prescription for each fill, though many doctors write multiple post-dated prescriptions at a single visit where state law allows.
- ID requirements. Pharmacies typically verify your identity when dispensing Schedule II drugs.
- Monitoring programs. Most states track Schedule II dispensing through prescription drug monitoring databases, which your prescriber and pharmacist can access.
How Azstarys Compares to Other ADHD Stimulants
Every methylphenidate and amphetamine-based ADHD medication on the market is Schedule II. What sets Azstarys apart isn’t its legal classification at the pharmacy counter, but the built-in abuse-deterrent chemistry of its prodrug component. Vyvanse (lisdexamfetamine) uses a similar prodrug strategy on the amphetamine side, and it’s also Schedule II despite evidence of lower abuse potential compared to immediate-release amphetamine.
Azstarys is FDA-approved for ADHD in patients 6 years and older and comes in three capsule strengths: 26.1 mg/5.2 mg, 39.2 mg/7.8 mg, and 52.3 mg/10.4 mg (prodrug/immediate-release). The most commonly reported side effects, drawn from data across methylphenidate products, include decreased appetite, insomnia, nausea, stomach pain, weight loss, anxiety, dizziness, irritability, increased heart rate, and higher blood pressure.
The short answer: Azstarys is a controlled substance with the same prescription restrictions as Ritalin or Concerta. Its prodrug design lowers its abuse potential in ways that clinical testing has confirmed, but federal law still treats the finished product under the stricter Schedule II rules because of the dexmethylphenidate it contains.